Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.

MLA

Farago, Anna F., and George D. Demetri. “Larotrectinib, a Selective Tropomyosin Receptor Kinase Inhibitor for Adult and Pediatric Tropomyosin Receptor Kinase Fusion Cancers.” Future Oncology (London, England), vol. 16, no. 9, Mar. 2020, pp. 417–25. EBSCOhost, https://doi.org/10.2217/fon-2019-0647.

APA

Farago, A. F., & Demetri, G. D. (2020). Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. Future Oncology (London, England), 16(9), 417–425. https://doi.org/10.2217/fon-2019-0647

Chicago

Farago, Anna F, and George D Demetri. 2020. “Larotrectinib, a Selective Tropomyosin Receptor Kinase Inhibitor for Adult and Pediatric Tropomyosin Receptor Kinase Fusion Cancers.” Future Oncology (London, England) 16 (9): 417–25. doi:10.2217/fon-2019-0647.